On August 19, 2026 Monteris Medical, the leader in minimally invasive neurosurgery with its NeuroBlate System for magnetic resonance-guided laser interstitial thermal therapy (LITT), reported the publication of the largest prospective dataset to date of patients undergoing LITT from its LAANTERN* study. Published in the distinguished Journal of Clinical Oncology (JCO), this ninth manuscript from LAANTERN analyzes outcomes from 787 tumor patients treated exclusively with NeuroBlate across 25 U.S. centers, establishing a new benchmark for clinical evidence in minimally invasive neurosurgery and highlighting key factors linked to increased survival.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This LAANTERN analysis demonstrates that extent of ablation (EOA) is a critical determinant of survival, particularly in newly diagnosed glioblastoma and recurrent metastatic tumors. Patients who achieved ≥91% tumor ablation experienced significantly longer progression-free and overall survival, establishing EOA as a central driver of post-LITT outcomes in newly diagnosed glioblastoma brain tumors.

"LAANTERN advances how LITT is understood and applied in neuro-oncology," said Dr. Eric C. Leuthardt, principal investigator of LAANTERN, lead author of the study and a professor of neurological surgery at Washington University School of Medicine in St. Louis. "I was an early investigator of this technology, and long-term outcomes from this large cohort will help us identify the patients who are most likely to benefit from this therapeutic option." Leuthardt treats patients at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, and is a research member of Siteman.

LAANTERN is the first – and remains the only – prospective multicenter study of this magnitude dedicated to LITT, with more than 1,000 patients enrolled and followed for up to five years. This latest publication from the LAANTERN study underscores Monteris’ sustained leadership and long-term commitment to generating rigorous, high-quality clinical evidence, culminating in outcomes data of unprecedented scale and significance for the field of minimally invasive neurosurgery.

NeuroBlate’s advanced engineering, including cooled laser probes that enable larger ablation volumes and the SideFire directional probe, which is specifically designed to address irregularly shaped lesions, optimizes the likelihood of achieving high EOA in real-world clinical practice.

For metastatic brain tumors, the study observed that earlier intervention, while lesions remain smaller, confers a survival advantage. This insight is particularly impactful for patients and providers as they make treatment decisions.

"These data show that timing matters," added Dr. Leuthardt. "Treating metastatic lesions earlier, before volume becomes prohibitive, improves patient outcomes and strengthens the role of LITT as a proactive cytoreductive option rather than a treatment of last resort."

Consistent with other publications from the LAANTERN study, patients undergoing NeuroBlate LITT experienced short hospital stays and rapid postoperative recovery, with the vast majority avoiding intensive care. Functional status and quality of life were largely preserved over time, with a favorable safety profile characterized by low complication and infection rates and few readmissions. Additional benefits included reductions in seizure burden and decreased reliance on steroids and anticonvulsant medications, supporting NeuroBlate as a minimally invasive option that promotes fast recovery while maintaining quality of life – areas of great importance to patients with brain tumors.

"Prior to the LAANTERN study, there was a lack of real-world evidence to support broad care team adoption, payer confidence and guideline inclusion," said Christa Seligman, senior director of clinical sciences at Monteris Medical. "It has been incredibly rewarding to lead a field that once did not have this foundation and to see that effort result in a publication of this caliber. Because of the dedicated LAANTERN clinical investigators and their patients, we are proud and humbled to continue leading with high-quality evidence that advances patient care."

*About LAANTERN

LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System, NCT02392078) is a post-market study designed to evaluate the performance and utilization of the NeuroBlate System to generate real-world evidence and guide standard of care practice. This is the first prospective multicenter laser ablation study. All sites operated under an IRB-approved protocol and received rigorous data monitoring to ensure quality and consistency. LAANTERN enrolled over 1,000 patients in the United States and followed them up to five years. Outcomes included safety, quality of life, health economics, procedural outcomes, seizure freedom, and survival.

About the NeuroBlate System

Monteris Medical develops and markets innovative MR‑guided laser ablation systems that enable minimally invasive, robotically controlled brain surgery – often referred to as laser ablation, LITT (laser interstitial thermal therapy) or SLA (stereotactic laser ablation). The company’s NeuroBlate System is designed for adults and children aged two and older and uses laser technology to precisely destroy abnormal brain tissue, including certain brain tumors and specific areas of the brain that cause seizures due to epilepsy. NeuroBlate is the only LITT platform with a robotic interface that supports the targeted, safe delivery of laser energy and is studied prospectively. Multicenter publications on NeuroBlate show that patients typically experience short hospital stays, low rates of complications, improved quality of life and outcomes comparable to open surgical resection.

(Press release, Monteris Medical, AUG 19, 2026, View Source [SID1234670231])

On August 19, 2026 Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medience") reported a collaboration to support genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following approval of a revision to the LC-SCRUM-Asia project protocol, the participating organizations plan to begin testing in August 2026. The project is expected to include approximately 2,000 patients over a two-year period.

Pillar’s oncoReveal Essential+ assay has been validated at LSI Medience for use as a screening test for circulating cell-free DNA (cfDNA) and cell-free RNA (cfRNA) samples collected from patients with lung cancer participating in the LC-SCRUM-Asia project. Testing will be performed by LSI Medience to support identification of genomic alterations relevant to the project’s research objectives.

"LC-SCRUM-Asia has established an important collaborative framework for advancing precision oncology research in lung cancer," said Daniel Harma, Chief Commercial Officer, Pillar Biosciences. "We are pleased that oncoReveal Essential+ has been validated at LSI Medience for screening both cfDNA and cfRNA samples and look forward to supporting this large-scale project in Japan."

"Rapid and reliable genomic testing is essential for identifying patients who may benefit from biomarker-driven clinical studies and emerging precision therapies," said Dr. Koichi Goto of LC-SCRUM-Asia. "The use of oncoReveal Essential+ through LSI Medience will provide the LC-SCRUM-Asia network with a highly accurate and accessible liquid biopsy solution for analyzing cfDNA and cfRNA from patients with non-small cell lung cancer, while supporting the rapid turnaround needed for clinical research."

Supporting blood-based genomic screening in lung cancer
Liquid biopsy testing can enable genomic analysis from blood samples when tissue is limited or when a minimally invasive sampling approach is desirable. By combining analysis of cfDNA and cfRNA, the LC-SCRUM-Asia project is designed to support broad screening for genomic alterations in patients with lung cancer.

The planned use of oncoReveal Essential+ within the LC-SCRUM-Asia project reflects the assay’s ability to support targeted NGS analysis from blood-based specimens within a decentralized laboratory workflow.

(Press release, Pillar Biosciences, AUG 19, 2026, View Source [SID1234670230])

On August 19, 2026 Xspray Pharma reported to have invited investors, analysts and media to a conference call following the company’s receipt of a Complete Response Letter, CRL, from the U.S. Food and Drug Administration, FDA, in relation to the company’s New Drug Application, NDA for Dasynoc. The receipt of the CRL was announced in a press release earlier today, 19 August 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, 20 August 2026
Time: 09:00 CEST
Speaker: Blake Leitch, CEO of Xspray Pharma
Language: English

The conference call will be hosted by Xspray Pharma’s CEO Blake Leitch, who will comment on the content of the CRL, the main remaining questions from the FDA and the company’s view of the next steps in the process. The presentation will be held in English and will conclude with a Q&A session.

If you wish to participate via webcast, please use the following link: View Source

Via the webcast, you are able to ask written questions.

If you wish to ask questions verbally via the teleconference, please register using the following link: View Source

After registration, you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

(Press release, Xspray, AUG 19, 2026, View Source [SID1234670228])

On August 19, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) reported positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma. The trial met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS). This represents the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy, as well as the first Phase 3 study to demonstrate a clinically meaningful improvement over KEYTRUDA alone, a standard-of-care immunotherapy, in the adjuvant setting for patients with resected melanoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At a pre-specified interim analysis, intismeran in combination with KEYTRUDA as adjuvant therapy demonstrated statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma who had not undergone prior treatment with systemic therapy. In accordance with the trial protocol, the study will continue in order to evaluate other key secondary endpoints, including overall survival (OS).

The safety profiles of intismeran and KEYTRUDA in this trial were consistent with those observed in previously reported studies for the combination, with no new safety signals observed.

These data will be presented at an upcoming international medical meeting and shared with regulatory authorities.

"Today’s results represent a landmark moment for adjuvant melanoma treatment. This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational ‘fingerprint’ of a patient’s own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death in patients with completely resected stage IIB-IV melanoma compared to KEYTRUDA alone," said Professor Georgina Long, the study’s principal investigator and medical director of Melanoma Institute Australia, Chair of Melanoma Medical Oncology and Translational Research at the University of Sydney. "Intismeran in combination with pembrolizumab has the potential to establish a new treatment paradigm in the adjuvant melanoma setting, helping patients remain cancer-free for longer."

"By intervening earlier in the course of disease, when many cancers are considered most treatable, the goal of adjuvant therapy given after surgery is to increase the possibility of cure for more patients," said Dr. Dean Y. Li, president, Merck Research Laboratories. "These first Phase 3 findings for intismeran in combination with KEYTRUDA as adjuvant therapy reinforce the promise of a more personalized approach to cancer treatment. We believe individualized neoantigen therapies have the potential to redefine how patients with completely resected stage IIB-IV melanoma are treated. Together with Moderna, we look forward to presenting data from INTerpath-001 at an international medical meeting and sharing with regulatory authorities."

"These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational. We are now helping turn that vision into a reality," said Stéphane Bancel, CEO of Moderna. "Together with Merck, we have started to demonstrate the transformative potential of this technology to address critical unmet needs in the adjuvant melanoma setting. We are deeply grateful to the patients, investigators and study teams whose contributions make this progress possible."

Merck and Moderna are advancing the robust INTerpath clinical development program evaluating the safety and efficacy of intismeran in combination with KEYTRUDA and other anti-cancer therapies, and as a monotherapy. The INTerpath program currently consists of nine total Phase 2 and Phase 3 clinical trials across multiple tumor types and stages of disease, including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma. Additional clinical studies include the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial in adjuvant melanoma and a Phase 1 study exploring adjuvant pancreatic ductal adenocarcinoma, perioperative gastric carcinoma and perioperative NSCLC.

Today’s Phase 3 readout builds on previously reported Phase 2b results for intismeran in combination with KEYTRUDA from the KEYNOTE-942/mRNA-4157-P201 trial, including the five-year follow-up data presented at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, in which the combination demonstrated a 49% reduction in the risk of recurrence or death (HR=0.51; [95% CI, 0.294-0.887]) and a 59% reduction in the risk of distant metastasis or death (HR=0.411; [95% CI, 0.200-0.843]) compared to KEYTRUDA alone.

About INTerpath-001
INTerpath-001 is a randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 trial (ClinicalTrials.gov, NCT05933577) evaluating the safety and efficacy of intismeran in combination with KEYTRUDA compared to KEYTRUDA alone in patients with high-risk (stage IIB-IV) resected cutaneous melanoma. The trial enrolled 1,137 patients who, following complete surgical resection, were randomized 2:1 to receive intismeran (1 mg every three weeks for up to nine doses) and KEYTRUDA (400 mg every six weeks up to nine cycles [for approximately one year]) versus KEYTRUDA alone for approximately one year until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever was sooner.

The primary endpoint is RFS, defined as the time from randomization to any disease recurrence (local, locoregional, regional or distant) as assessed by the investigator, or death due to any cause. Key secondary endpoints include DMFS, OS, safety, tolerability and quality of life.

About intismeran autogene
Intismeran autogene (intismeran; V940 or mRNA-4157) is a novel, potential first-in-class investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) jointly developed by Merck and Moderna. Intismeran is designed and produced using a patient’s tumor sample to identify the unique mutational signature, or "fingerprint," of their cancer and generate an anti-tumor immune response. Each therapy consists of a synthetic mRNA coding for up to 34 neoantigens and is tailored to the unique biology of an individual patient’s tumor. Upon administration, the RNA-encoded neoantigen sequences are translated in the body and presented to the immune system, a key step in generating specific T-cell responses against cancer cells. Individualized neoantigen therapies are designed to train and activate an anti-tumor immune response based on the unique mutational signature of a patient’s tumor.

About melanoma
Melanoma, one of the deadliest forms of skin cancer, is characterized by the uncontrolled growth of pigment-producing cells. The rates of melanoma have been rising over the past few decades, with more than 330,000 new cases diagnosed worldwide in 2022. In the U.S., skin cancer is one of the most common types of cancer diagnosed, and melanoma accounts for a large majority of skin cancer deaths. It is estimated there will be about 112,000 new cases of melanoma diagnosed and over 8,500 deaths resulting from the disease in the U.S. in 2026 alone. Despite advances in treatment, patients with resected melanoma remain at risk of disease recurrence, which most often occurs within the first two years. The majority of recurrences are metastatic rather than localized, highlighting the ongoing need for treatment approaches that may help reduce the risk of recurrence and improve long-term outcomes.

(Press release, Merck & Co, AUG 19, 2026, View Source [SID1234670226])

On August 19, 2026 Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, reported financial and operating results for the second quarter ended June 30, 2026, and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, said, "The planned merger with Scipher Medicine continues to advance. As we have reported, Scipher’s validated AI network medicine platform, SPECTRA, identified nebokitug as the leading candidate to address a major unmet need in rheumatoid arthritis (RA), a $24 billion market. We believe this merger provides our shareholders a compelling opportunity to potentially realize value through the clinical advancement of nebokitug in a large indication, as well as through Scipher’s revenue-generating precision medicine business and its biopharma partnerships. The opportunity also remains to secure a potential partner for a nebokitug Phase 3 trial in primary sclerosing cholangitis (PSC), an indication with no FDA-approved therapies. We look forward to working with our colleagues at Scipher to complete the proposed transaction and expedite the initiation of the Phase 2 trial in RA, marking an important new phase in the development of nebokitug and our anti-CCL24 platform."

Reg Seeto, MBBS, Chief Executive Officer of Scipher Medicine, said, "We believe the announced strategic merger with Chemomab is a unique opportunity to transform the treatment of immunology-based diseases with precision medicine. We plan to start with nebokitug in patients with rheumatoid arthritis, which like other immunology-based diseases is complex in origin. This complexity results in a heterogeneous patient population with unmet medical needs, since one-size-fits-all therapies do not work well for many patients. In RA, this approach has resulted in the majority of moderate-to-severe patients not achieving an enduring response, despite multiple available treatment options."

Dr. Seeto continued, "We reached out to Chemomab because SPECTRATM, our validated AI-enabled network medicine platform, had identified nebokitug’s novel mechanism as the highest ranked clinical program for potentially achieving efficacy in RA compared to both current and pipeline drugs in development. We intend to develop a nebokitug-specific molecular treatment-response signature (MTRS) using the technology that built the only MTRS approved by CMS in immunology. We believe this technology could increase the probability of clinical success, as we preferentially target the population that may benefit from nebokitug. Oncology has already demonstrated patient benefit with precision medicine by improving outcomes in a targeted population and has expanded the overall market with this approach of the right drug for the right patient. We see the field of immunology as the next frontier for precision medicine and we are already leading the way.

Second Quarter 2026 and Recent Highlights:

Entered into Definitive Merger Agreement with Scipher Medicine. On July 8, 2026, Chemomab announced that it had entered into a definitive merger agreement (the "Merger Agreement") with Scipher Medicine Corporation pursuant to which the companies will combine in an all-stock transaction (the "Merger"). Under the terms of the Merger Agreement, Chemomab equity holders are expected to own approximately 32% of the combined company, with Scipher equity holders owning approximately 68%, subject to customary adjustments. The combined company is valued at $150 million prior to a concurrent $30 million private placement financing and is expected to have sufficient cash to fund operations through the readout of the nebokitug Phase 2 RA trial. The private placement is being led by a syndicate of current Scipher investors, including Northpond Ventures, with participation from Khosla Ventures, Blue Owl Healthcare Opportunities, funds managed by Neuberger, and other leading investors, and includes 100% warrant coverage, with the warrants having an exercise price based on a $75 million valuation. In addition, immediately following the closing, Chemomab shareholders will receive contingent value rights (CVRs), providing the opportunity to receive future cash payments of $10 million upon U.S. Food and Drug Administration approval of nebokitug for any indication and $40 million if Chemomab’s PSC program advances to a Phase 3 clinical trial or is partnered, in each case subject to the terms and conditions of the CVR agreement. Upon completion of the Merger, the combined company is expected to operate as Scipher Medicine Corporation and trade on the Nasdaq Capital Market under the ticker symbol "SCIP." The combined company plans to initially focus on advancing nebokitug, a first-in-class clinical stage anti-CCL24 antibody, into a Phase 2 clinical trial for the treatment of rheumatoid arthritis, with topline results expected in the first half of 2028. Following the closing, Dr. Reginald Seeto will serve as Chief Executive Officer of the combined company, and Chemomab co-founder and Chief Executive Officer Dr. Adi Mor will join the combined company’s Board of Directors.
​
Presented three abstracts on May 30, 2026 at EASL 2026, the Annual Congress of the European Association for the Study of the Liver in Barcelona, Spain.

In one EASL 2026 study1, Olink-generated analyses of circulating proteins in patient samples from the nebokitug PSC Phase 2 SPRING trial were used to generate an AI/machine learning model to identify patients who showed a combined improvement in three key fibrosis-related measures. The model showed strong performance and reliability, accurately distinguishing patients who met the combined improvement definition from those who did not.

A second EASL 2026 study2 examined the impact of nebokitug treatment on four PSC-specific gene expression programs (GEPs). Treatment with nebokitug was associated with statistically significant and dose-dependent reductions in the signatures linked to the PSC-related fibrotic and immune proteins. These findings provide further support for nebokitug’s CCL24 blocking activity as a mechanism-based approach targeting core molecular drivers of PSC pathogenesis.

A third EASL 2026 study3 examined nebokitug and its CCL24 target in patients with both PSC and inflammatory bowel disease (IBD). This study evaluated whether CCL24 inhibition modulates inflammatory and tissue-remodeling signatures relevant to PSC-IBD pathogenesis. The authors conclude that treatment with nebokitug resulted in improvements across inflammatory and tissue-remodeling proteins relevant to PSC with coexisting intestinal inflammation from ulcerative colitis and Crohn’s disease. These findings suggest that CCL24 inhibition may beneficially impact shared gut–liver inflammatory circuits in patients with co-existing PSC and IBD.

Presented new data from the company’s Phase 2 SPRING trial of nebokitug in PSC in an oral presentation at Digestive Disease Week (DDW 2026)4. On May 4, 2026, a new proteomic study showed that treatment with nebokitug resulted in dose-dependent reductions in multiple inflammatory and tissue-remodeling signatures relevant to both PSC and IBD. The authors conclude that inhibition of nebokitug’s CCL24 target may provide meaningful benefit in PSC patients with concomitant IBD.
1 – AI-driven proteomic profiling differentiates composite improvement following treatment with nebokitug in PSC; T. Snir, R. Aricha, J. Lawler, C Cirillo, D. Weiner, and A. Mor; EASL 2026 Abstract No. 1839; Immune-mediated and cholestatic disease: Clinical aspects; May 30, 2026, 8:30 – 16:00 CEDT

2 – Nebokitug down-regulates core fibrotic and immune pathways defined by single-cell liver profiling; R Aricha, T Snir, J Lawler, C Cirillo, D Weiner, A Mor; EASL 2026 Abstract No. 1852; Immune-mediated and cholestatic disease: Clinical aspects; May 30, 2026, 8:30 – 16:00 CEDT

3 – Nebokitug modulates gut-liver inflammatory and tissue remodeling signatures in PSC patients with coexisting IBD; R Aricha, T Snir, J Lawler, C Cirillo, D Weiner, and A Mor; EASL 2026 Abstract No. 1859; Immune-mediated and cholestatic disease: Clinical aspects; May 30, 2026, 8:30 – 16:00 CEDT

4 – Nebokitug modulates inflammatory and tissue-remodeling signatures in patients with PSC and coexisting IBD: Biomarker findings from SPRING Phase 2 trial; P. Mantry, T Snir, R Aricha, J Lawler, C Cirillo, D Weiner, A Mor; DDW 2026 Abstract No. 4484827, Advances in the Management of Primary Sclerosing Cholangitis; May 4, 2026, 2:00 – 3:30 PM CDT

Second Quarter 2026 Financial Highlights:

Cash Position: Cash, cash equivalents and short-term bank deposits were $6.7 million as of June 30, 2026, compared to $8.0 million as of March 31, 2026.

Research and Development (R&D) Expenses: R&D expenses were $1.1 million for the second quarter of 2026, compared to $1.3 million for the second quarter of 2025.

General and Administrative (G&A) Expenses: G&A expenses were $1.1 million for the second quarter of 2026, compared to $1.0 million for the second quarter of 2025.

Net Loss: Net loss was $2.2 million, or a net loss of less than $0.01 per basic and diluted ordinary share, for the second quarter of 2026, compared to $2.1 million, or a net loss of less than $0.01 per basic and diluted ordinary share, for the second quarter of 2025. The weighted average number of ordinary shares outstanding, basic and diluted, was 640,243,933 (equal to approximately 8,003,049 ADSs) for the second quarter of 2026.

Liquidity and Capital Resources: Chemomab believes its existing liquidity resources as of June 30, 2026 will enable it to fund its operations through the first quarter of 2027.

Number of Issued and Outstanding Shares: As of June 30, 2026, the company had 579,648,600 issued and outstanding shares compared to 575,381,320 as of December 31, 2025.
Merger Update
Chemomab has confidentially submitted a draft registration statement on Form S-4 to the U.S. Securities and Exchange Commission (SEC) in connection with its proposed Merger with Scipher Medicine. The confidential submission enables the SEC review process to begin while certain required financial information is being finalized, helping to support the transaction timeline. The registration statement is expected to be publicly filed following the SEC’s initial review process, in accordance with applicable SEC rules. The companies expect the Merger to close before the end of 2026, subject to SEC review, shareholder approvals and other customary closing conditions. For additional information, please refer to the company’s Form 6-K filed with the SEC today.

(Press release, Chemomab, AUG 19, 2026, View Source [SID1234670225])